# Novartis AG > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Novartis AG). ## Overview Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas. Its business is organized around innovative branded pharmaceuticals and a portfolio of established medicines sold through global healthcare channels. ## Products & services • Prescription medicines in immunology, neuroscience, oncology, and cardiovascular disease • Cell and gene therapies, including Zolgensma • Established brands and mature medicines • Global drug development, regulatory, and commercialization capabilities - **Innovative medicines** (78%) — Branded prescription drugs for chronic, rare, and specialty diseases. - **Immunology** (18%) — Therapies for autoimmune and inflammatory conditions such as Cosentyx and Xolair. - **Neuroscience** (10%) — Medicines for neurological and neuromuscular disorders, including Kesimpta and Zolgensma. - **Oncology** (20%) — Cancer therapies and targeted treatments for hematology and solid tumors. - **Cardiovascular, renal and metabolism** (14%) — Drugs for cardiovascular and metabolic diseases, including several mature brands. - Prescription medicines in immunology, neuroscience, oncology, and cardiovascular disease - Cell and gene therapies, including Zolgensma - Established brands and mature medicines - Global drug development, regulatory, and commercialization capabilities ## Customers Novartis sells primarily to healthcare providers, hospitals, specialty clinics, and pharmacies that dispense prescription medicines to patients. It also serves governments, payers, and other reimbursement systems that influence access and pricing for branded therapies. Demand is driven by disease prevalence, clinical adoption, reimbursement coverage, and the launch cycle of new medicines. - **Healthcare providers** (primary) — Hospitals, specialists, and clinics prescribing Novartis therapies for specific diseases. - **Payers and governments** (primary) — National health systems and insurers that determine reimbursement and access terms. - **Pharmacies and distributors** (secondary) — Channel partners that dispense and distribute prescription medicines to patients. - **Patients** (primary) — End users of Novartis medicines, especially in chronic and specialty indications. - Hospitals and specialty clinics treating complex diseases - Physicians and healthcare systems prescribing branded therapies - Pharmacies and distributors that channel prescription medicines - Public and private payers that negotiate access and reimbursement - Patients with chronic, rare, and specialty conditions ## Geography Novartis operates globally, with product sales and clinical activity spanning the Americas, Europe, Asia-Pacific, and other international markets. The company’s exposure is shaped by national reimbursement systems, patent regimes, and currency movements, while manufacturing and supply chains support a worldwide branded-drug franchise. The excerpts provided do not include an authoritative revenue-by-country table, so the profile reflects the company’s global operating footprint rather than a country map. - Global sales footprint across the Americas, Europe, and Asia-Pacific - Swiss-based corporate structure with worldwide operating subsidiaries - Local reimbursement and pricing rules affect market access by country - Currency swings matter because revenue and costs are spread globally - Supply and manufacturing must support regulated pharmaceutical markets ## Strategy Novartis focuses on building its pipeline and advancing selected late-stage compounds while defending and extending key branded products. The company also emphasizes lifecycle management, external business opportunities, and technology-enabled development to strengthen its long-term medicines portfolio. Its strategy is tied to sustaining innovation in areas with high unmet medical need and durable reimbursement support. - **Pipeline progression** (medium-term) — New approvals replace lost exclusivity and sustain the branded medicines franchise. - **Lifecycle management** (short-term) — Extensions and new indications can preserve demand for major products. - **External growth** (medium-term) — Acquisitions and collaborations can add platform technologies and assets. - **Operational and digital capability** (medium-term) — IT, data, and AI investments support research productivity and commercialization. - Advance late-stage pipeline candidates toward approval and launch - Support key brands with lifecycle management and new indications - Use external business opportunities to broaden the portfolio - Invest in technology, including AI and IT systems, for R&D and operations - Protect intellectual property and exclusivity around core medicines ## Risks Novartis faces the standard pharmaceutical risks of patent expiry, pricing pressure, clinical trial setbacks, and regulatory scrutiny, all of which can disrupt product demand and pipeline value. The report also highlights operational and geopolitical exposures, including tariffs, war-related disruption, foreign exchange swings, cybersecurity, and manufacturing quality issues. Because the business depends on a small number of key medicines and global reimbursement systems, these risks can affect revenue durability and launch timing. - **Loss of patent protection and exclusivity** [high] — Novartis relies on branded medicines that face generic or biosimilar competition over time. - **Healthcare pricing and reimbursement pressure** [high] — Governments and payers can force lower prices, stricter access, or transparency requirements. - **Clinical development and regulatory risk** [high] — Pipeline candidates depend on trial success, approvals, and post-approval oversight. - **Foreign exchange and geopolitical disruption** [medium] — Global operations create exposure to currency movements, tariffs, and regional conflict. - **Manufacturing and quality issues** [high] — Pharmaceutical production must meet strict standards, and failures can delay supply or trigger remediation. - Patent expiry and loss of exclusivity can reduce sales of key medicines - Pricing and reimbursement pressure can constrain access and pricing power - Clinical trial outcomes may delay or eliminate pipeline value - Tariffs, war, and FX swings can disrupt supply and reported results - Manufacturing, quality, and data integrity issues can trigger interruptions ## Accounting Novartis reports under IFRS and uses judgment-heavy estimates for revenue, provisions, fair values, and contingent matters common in pharmaceuticals. The excerpts also note that IFRS 18 will change income statement and cash flow presentation from 2027, while not affecting net income, and that acquisitions such as Avidity Biosciences introduce fair value and purchase accounting complexity. Investors should also watch goodwill and intangible asset valuation, because the business depends heavily on acquired and developed drug assets. - **IFRS 18 transition** — Reclassification of foreign exchange, interest, dividends, and cash flow line items - **Business combinations** — Purchase price allocation, amortization, and potential goodwill - **Revenue deductions** — Net sales timing and amount - **Impairment of intangibles** — Earnings volatility and balance sheet write-down risk - IFRS 18 will change presentation of income and cash flow lines - Acquisitions require purchase accounting and fair value allocation - Revenue estimates may depend on rebates, discounts, and returns - Intangible assets and goodwill are vulnerable to impairment testing - Provisions and contingencies can affect results in regulated markets --- *Last updated: 2026-09-28T12:13:22.123109+00:00*